Special Issue "Cutaneous Complications of Targeted Cancer Therapy"

A special issue of Medicina (ISSN 1010-660X). This special issue belongs to the section "Dermatology".

Deadline for manuscript submissions: 15 July 2021.

Special Issue Editor

Prof. Dr. Mauro Salvatore Alessandro Alaibac
Website
Guest Editor
Department of Dermatology, University of Padua, Padova, Italy
Interests: cutaneous oncology; immunodermatology

Special Issue Information

Dear Colleagues,

Research in cancer development has led to the rapid emergence of numerous targeted anticancer therapies in the last decade. Targeted therapies, unlike standard chemotherapy agents that lead to systemic toxicities, are frequently associated with cutaneous adverse events, which may be responsible for dose reduction or therapy discontinuation. Given the rapid development of targeted anticancer treatments, dermatologists will be essential for the recognition of these cutaneous complications, particularly as the presence of dermatologic toxicities has been shown to have a positive correlation with response to therapy. Skin adverse events significantly influence the quality of life of patients under treatment with targeted drugs.

Authors are invited to submit research papers, reviews, clinical studies, and case reports concerning this issue.

Prof. Dr. Mauro Salvatore Alessandro Alaibac
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Medicina is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1500 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • targeted therapies
  • immunotherapy
  • cutaneous toxicity
  • anti-cancer drugs
  • adverse drug reaction
  • skin rash

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Other

Open AccessCase Report
Sarcoma as Second Cancer in a Childhood Cancer Survivor: Case Report, Large Population Analysis and Literature Review
Medicina 2020, 56(5), 224; https://doi.org/10.3390/medicina56050224 - 07 May 2020
Cited by 1
Abstract
The majority of pediatric patients are cured of their primary cancer with current advanced developments in pediatric cancer therapy. However, survivors often experience long-term complications from therapies for primary cancer. The delayed mortality rate has been decreasing with the effort to reduce the [...] Read more.
The majority of pediatric patients are cured of their primary cancer with current advanced developments in pediatric cancer therapy. However, survivors often experience long-term complications from therapies for primary cancer. The delayed mortality rate has been decreasing with the effort to reduce the therapeutic exposure of patients with pediatric cancers. Our study investigates the incidence of sarcoma as second cancer in pediatric cancer survivors. We present a 9-year-old male who survived embryonal hepatoblastoma diagnosed at 22 months of age. At 4.5 years of age, he presented with a non-metastatic primitive neuroectodermal tumor (PNET) of the left submandibular area. He has no evidence of recurrence of either cancer for 51 months after finishing all chemotherapy and radiotherapy. We used the Surveillance, Epidemiology, and End Results (SEER) database to identify the current rate of second sarcomas in pediatric cancer survivors. Our literature review and large population analysis emphasize the impact of sarcoma as a second malignancy and provide help to physicians caring for pediatric cancer survivors. Full article
(This article belongs to the Special Issue Cutaneous Complications of Targeted Cancer Therapy)
Show Figures

Figure 1

Back to TopTop